Get the Daily Brief
Latest Biotech News
Big tech and lab automation collide: NVIDIA deals with Thermo Fisher and Lilly
Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to embed the company’s AI platform into scientific instruments and lab workflows, aiming to accelerate automation,...
Cellares expands IDMO footprint with Leiden Smart Factory lease
Cellares signed a long‑term lease for a new integrated development and manufacturing organization (IDMO) Smart Factory in Leiden Bio Science Park to serve as the company’s European headquarters....
Gene‑drive mosquitoes validated against diverse malaria strains in Tanzania
Researchers adapted a previously developed gene‑drive strategy and tested it in secure facilities in Tanzania, engineering Anopheles mosquitoes to express antiparasitic effectors (MM‑CP) and...
FDA grants RMAT to iRegene’s iPSC‑derived Parkinson’s therapy
The U.S. FDA awarded Regenerative Medicine Advanced Therapy (RMAT) designation to iRegene’s NouvNeu001, making it the first allogeneic iPSC‑derived cell therapy to hold both FDA Fast Track and...
Off‑the‑shelf CAR‑NK: Durable complete responses in Waldenström
Early clinical data show an allogeneic CAR‑NK therapy produced durable complete responses in patients with Waldenström’s macroglobulinemia when combined with anti‑CD20 therapy. ImmunityBio...
ARPA‑H backs UCSD: $25.8M push to 3D‑print patient‑specific livers
UC San Diego won a long‑term ARPA‑H award to develop patient‑specific, 3D‑bioprinted human livers with the goal of creating transplant‑ready organs from a patient’s own cells. The five‑year,...
Novo Nordisk Foundation Pours DKK5.5B ($850M) into BioInnovation Institute
The Novo Nordisk Foundation committed up to DKK 5.5 billion (about $850–$857 million) to Denmark’s BioInnovation Institute to scale early‑stage life‑science commercialization across Europe. The...
Tecvayli survival win: J&J reports major Phase 3 benefit in multiple myeloma
Johnson & Johnson announced Phase 3 results showing Tecvayli improved survival and progression‑free outcomes in patients with relapsed multiple myeloma compared with standard regimens, per company...
Boston Scientific to buy Penumbra for $14.5B – Big play in thrombectomy
Boston Scientific agreed to acquire Penumbra for $14.5 billion in cash and stock to expand into thrombectomy and embolization devices, the companies announced. The deal adds Penumbra’s...
FDA grants RMAT to iRegene’s iPSC therapy – Regulatory double‑play for Parkinson’s
The FDA awarded Regenerative Medicine Advanced Therapy (RMAT) designation to iRegene Therapeutics’ lead off‑the‑shelf, chemically induced iPSC product NouvNeu001 for Parkinson’s disease, adding to...
BloodPAC issues MRD validation protocols – Toward analytic standards for ctDNA
The BloodPAC consortium published generic analytic validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays aimed at minimal residual disease (MRD) monitoring. The protocols,...
Myriad maps MRD rollout: Sequenced launches and reimbursement playbook
Myriad Genetics outlined a staged commercial plan for tissue‑informed MRD assays, beginning with a breast cancer MRD test in early 2026 and follow‑on launches for renal, colorectal, endometrial,...
Cellares inks Leiden smart‑factory lease – Regional IDMO capacity for cell therapies
Cellares signed a long‑term lease at Leiden Bio Science Park to establish a European Smart Factory using its automated Cell Shuttle manufacturing platforms and Cell Q quality systems. The...
Vedanta trims workforce to fund VE303 Phase 3 push – Cash‑constrained refocus
Vedanta Biosciences said it significantly reduced headcount to concentrate capital and manpower on its lead live‑biotherapeutic VE303, a bacterial consortium targeting recurrent Clostridioides...
Epkinly misses overall survival: AbbVie, Genmab report Phase 3 setback
AbbVie and Genmab announced that Epkinly failed to prolong overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The multicenter study enrolled patients who had received...
Off‑the‑shelf CAR‑NK posts complete responses up to 15 months — ImmunityBio
ImmunityBio reported encouraging early results from its off‑the‑shelf CD19 CAR‑NK program in a small Phase 1 cohort for Waldenström’s lymphoma, with complete responses sustained up to 15 months in...
Tecvayli tops standard regimens — J&J reports survival and progression wins
Johnson & Johnson reported Phase 3 data showing Tecvayli improved outcomes versus widely used regimens in earlier settings of multiple myeloma. In the MajesTEC‑9 study, J&J said patients...
ARPA‑H backs patient‑specific 3D livers: UC San Diego wins $25.8M
The Advanced Research Projects Agency for Health (ARPA‑H) awarded UC San Diego up to $25,771,771 to develop patient‑specific, 3D bioprinted human livers under the agency’s PRINT program. The...
FDA grants RMAT to iRegene’s iPSC therapy: NouvNeu001 earns accelerated pathway
iRegene Therapeutics said the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to its allogeneic iPSC‑derived product NouvNeu001 for Parkinson’s disease, adding to an existing...
Boston Scientific to buy Penumbra for $14.5B — bet on thrombectomy and embolization
Boston Scientific announced an agreement to acquire Penumbra for approximately $14.5 billion to expand into thrombectomy and embolization markets, the companies said. The deal would add Penumbra’s...